NASDAQ · Shell Companies · USD

Translational Development Acquisition Corp. (TDAC) Stock Analysis

Translational Development Acquisition Corp. (TDAC) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

TDAC

$10.85

−$0.00 (−0.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TDAC with… →

TDAC Key Statistics

As of Sep 4, 2026

Trading

Open: $10.85
Previous Close: $10.85
Day's Range: 10.84–10.85
52-Week Range: 10.33–10.95
Volume: 8.40K

Valuation

Market Cap: $209.40M
P/E Ratio: 41.71
EPS (ttm): 0.26

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $6.36M
Profit margin: 0.00%
Shares Outstanding: 19.31M
1-Year Return: +4.88%

Dividend and dates

Avg Volume: 43.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TDAC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+3.38%
2025 (partial year)	+4.80%

As of September 4, 2026.

TDAC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	$6.36M	—
2024	$0.00	−$71.01K	—
2023	$0.00	−$485.55K	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$944.54K	$6.36M	—
2024	$0.00	—	−$196.36K	−$71.01K	—
2023	$0.00	—	−$485.55K	−$485.55K	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TDAC Valuation vs Shell Companies Median

Median of 587 stocks

Metric	TDAC	Shell Companies median	vs median
P/E	41.71	45.20	8% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Translational Development Acquisition Corp. (TDAC) at $209.40M. It is classified in the Shell Companies industry, within the Financial Services sector.

Over the past 52 weeks the price has ranged from $10.33 to $10.95. TDAC last closed at $10.85 on September 4, 2026. That is $0.00 (−0.05%) against the previous close. The latest close sits 4.99% above that 52-week low.

Financial Health

In fiscal 2025, Translational Development Acquisition Corp. reported revenue of $0.00. Net income for the same year was $6.36M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 0.26.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 41.71. That is 7.72% below the Shell Companies median of 45.2. 587 Shell Companies companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +4.88%. The stored price history starts on February 13, 2025, and the total return since then is +8.34%. Annualized volatility over the trailing 1 year is 2.42%.

Growth & Income

No dividend is on file for TDAC.

So far in 2026 the price is +3.38%.

Peer Comparison

Translational Development Acquisition Corp. (TDAC) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Translational Development Acquisition Corp.	TDAC	$209.40M	41.7
Churchill Capital Corp XI	CCXI	$746.38M	—
Churchill Capital Corp X	CCCX	$711.00M	—
Drugs Made In America Acquisition II Corp.	DMII	$647.83M	35.1

The Shell Companies industry average P/E ratio is 45.2x. Translational Development Acquisition Corp. trades at a P/E of 41.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

DMII

Drugs Made In America Acquisition II Corp.

$647.83M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

Visit website →